0001209191-23-059628.txt : 20231222
0001209191-23-059628.hdr.sgml : 20231222
20231222184518
ACCESSION NUMBER: 0001209191-23-059628
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231221
FILED AS OF DATE: 20231222
DATE AS OF CHANGE: 20231222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pizzuti Dana
CENTRAL INDEX KEY: 0001948238
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 231511079
MAIL ADDRESS:
STREET 1: C/O CRINETICS PHARMACEUTICALS, INC.
STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-21
0
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001948238
Pizzuti Dana
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD
SAN DIEGO
CA
92121
0
1
0
0
Chief Med and Dev Officer
0
Common Stock
2023-12-21
4
M
0
9583
16.89
A
15494
D
Common Stock
2023-12-21
4
S
0
9583
34.57
D
5911
D
Non-qualified stock option (Right to Buy)
16.89
2023-12-21
4
M
0
9583
0.00
D
2032-10-10
Common Stock
9583
220417
D
Includes 1,411 shares acquired under the Issuer's Employee Stock Purchase Plan.
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $34.57 per share. The range of sales prices on the transaction date was $34.50 to $34.67 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
/s/ Marc Wilson, as attorney-in-fact
2023-12-22